Y51.8
Centrally acting and adrenergic-neuron-blocking agents, not elsewhere classified
⇄ Primary-code rule changed vs QĐ4469
Coding rules (TT06)
- ●Cannot be used as primary diagnosis
Coding guidance (WHO 2019)
Excl.: clonidine (Y52.5) guanethidine (Y52.5)
Sibling codes
Y51Drugs primarily affecting the autonomic nervous systemY51.0Anticholinesterase agentsY51.1Other parasympathomimetics [cholinergics]Y51.2Ganglionic blocking drugs, not elsewhere classifiedY51.3Other parasympatholytics [anticholinergics and antimuscarinics] and spasmolytics, not elsewhere classifiedY51.4Predominantly alpha-adrenoreceptor agonists, not elsewhere classifiedY51.5Predominantly beta-adrenoreceptor agonists, not elsewhere classifiedY51.6Alpha-adrenoreceptor antagonists, not elsewhere classifiedY51.7Beta-adrenoreceptor antagonists, not elsewhere classifiedY51.9Other and unspecified drugs primarily affecting the autonomic nervous system